Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Jul 27, 2021 3:07pm
136 Views
Post# 33611339

RE:RE:RE:RE:An article on lung cancer

RE:RE:RE:RE:An article on lung cancer
99942Apophis wrote: That sounds correct tdon1229  my thought at the time was they were hoping the Photofrin in a new and improved version would be equal to or in the same Roswell Park (pun)  as the Theralase product. It still is my opinion that they didn't want a competitive product to outshine theirs. 


Hi Apophis....Porfirmer sodium is no longer patent protected & I can't imagine Photofrin is a big money maker for Roswell at this point.  Why else would Roswell agree to participate in an in vitro study of TLD 1433 other than to basically find a better option to the limited first generation PS (Photofrin).  The very positive in vitro results of TLD 1433 (& likely its future derivatives imo) showed great potential to put their illustrious PDT program back on the map.  Either the drug is still being studied/considered for a future trial or there is some other non-scientific reason, & I don't think it's related to Roswell not being interested.  All JMO.
<< Previous
Bullboard Posts
Next >>